Author: admin

“ANCA associated Vasculitis Market Insight, Epidemiology And Market Forecast – 2034”

DelveInsight’s “ANCA associated Vasculitis Market Insight, Epidemiology And Market Forecast – 2034” report delivers a comprehensive analysis of the ANCA-Associated Vasculitis market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways

• Market size projection: As per DelveInsight’s analysis, the total ANCA-associated Vasculitis market size in the 7MM is expected to surge significantly by 2034, with the market valued at approximately USD 1.5 billion in 2023.

• Patient population data: The report provides the total ANCA-associated Vasculitis potential pool of approximately 215K diagnosed prevalent cases across the 7MM in 2023, with the United States contributing the highest number of cases, followed by Japan.

• Key companies: Leading ANCA-associated Vasculitis companies, such as GlaxoSmithKline, AstraZeneca, InflaRx, Staidson BioPharma, Bio-Thera Solutions, and ChemoCentryx/Amgen, are actively developing innovative therapeutic solutions.

• Pipeline assets: Some of the key ANCA-associated Vasculitis pipeline drugs include Depemokimab (GSK3511294) by GlaxoSmithKline and FASENRA (benralizumab) by AstraZeneca, among others.

• As per DelveInsight’s patient-based forecasting model, NUCALA (mepolizumab) and rituximab accounted for the highest ANCA-associated Vasculitis market share among available therapies in the 7MM.

• A comprehensive analysis published in March 2025 noted that ANCA-associated vasculitis drug development has focused on improved b cell targeting through stronger b cell depletion, b cell cytokine inhibition, newer b cell directed cell therapies and broader complement inhibitors inspired by avacopan’s success.

• In April 2025, the FDA approved upadacitinib (Rinvoq) for treating adults with giant cell arteritis (GCA). While this approval is specifically for GCA rather than ANCA-associated vasculitis, it represents significant progress in vasculitis treatment and may have implications for future AAV research.

• In March 2023, Vifor Fresenius Medical Care Renal Pharma announced that TAVNEOS has been included in the revised EULAR ANCA-associated Vasculitis management recommendations.

• In September 2023, AstraZeneca reported positive high-level results from the MANDARA Phase III trial for FASENRA, demonstrating non-inferior rates of remission compared to mepolizumab in patients with EGPA.

Discover recent advancements in the ANCA-Associated Vasculitis treatment landscape @ ANCA-Associated Vasculitis Recent Developments.

ANCA-associated Vasculitis Market Dynamics

The ANCA-associated Vasculitis market represents a significant therapeutic opportunity within rare autoimmune diseases, characterized by substantial unmet medical needs and emerging innovative treatment approaches. The current ANCA-associated Vasculitis treatment landscape is dominated by established immunosuppressive therapies, with the market valued at approximately USD 1.5 billion in 2023 across the 7MM countries. This market is experiencing robust momentum driven by the launch of novel targeted therapies and an improved understanding of disease pathophysiology.

ANCA-associated Vasculitis market drivers include the recent approval and commercial success of TAVNEOS (avacopan), the first-in-class complement 5a receptor (C5aR) antagonist that represents a paradigm shift in ANCA-associated Vasculitis treatment. The current treatment paradigm relies heavily on cyclophosphamide, rituximab, and high-dose corticosteroids for remission induction, followed by maintenance therapy with methotrexate or azathioprine. While these therapies demonstrate efficacy in inducing and maintaining remission, they are associated with significant toxicities, creating substantial opportunities for safer, more targeted interventions.

The ANCA-associated Vasculitis emerging therapies focus on precision targeting of inflammatory pathways involved in vasculitic processes. TAVNEOS operates through a novel mechanism by blocking the complement 5a receptor, effectively interrupting the complement-driven inflammatory cascade that characterizes ANCA-associated Vasculitis. Similarly, the IL-5 pathway targeting approach employed by therapies like FASENRA (benralizumab) and Depemokimab represents a sophisticated understanding of eosinophil-mediated pathology, particularly relevant in EGPA management.

ANCA-associated Vasculitis clinical development activity remains robust, with multiple Phase III trials demonstrating the industry’s commitment to addressing this rare disease population. The MANDARA trial for FASENRA represents the first head-to-head comparison of biologics in EGPA, while the ongoing OCEAN trial for Depemokimab promises to further expand treatment options. The competitive landscape includes major pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and InflaRx, each pursuing distinct therapeutic approaches and patient populations.

Despite significant progress, the market faces challenges, including diagnostic delays that lead to increased morbidity and mortality, highlighting the critical need for reliable biomarkers and early detection strategies. However, these challenges simultaneously represent opportunities for companies developing diagnostic tools and precision medicine approaches. Future market growth is expected to be driven by the anticipated launch of emerging therapies, improved diagnostic capabilities, and expanding understanding of disease heterogeneity across the three main subtypes: granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.

Download the ANCA-Associated Vasculitis Market report to understand which factors are driving the therapeutic market @ ANCA-Associated Vasculitis Market Trends.

ANCA-associated Vasculitis Epidemiology

The epidemiological landscape of ANCA-associated Vasculitis across the 7MM reveals a complex distribution pattern with significant regional variations and distinct subtype prevalence characteristics. The total diagnosed prevalent cases reached approximately 215K across the seven major markets in 2023, establishing a substantial patient population requiring specialized therapeutic interventions. This patient population represents individuals affected by three primary disease subtypes: granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, each presenting unique clinical challenges and treatment requirements.

Epidemiological segmentation demonstrates interesting patterns in disease distribution and organ involvement. Among the three ANCA-associated Vasculitis subtypes, granulomatosis with polyangiitis shows higher prevalence compared to microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis across most markets. However, regional variations exist, with Japan showing a different pattern where microscopic polyangiitis accounts for the highest number of cases, followed by granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis. This geographic variation reflects genetic, environmental, and potentially diagnostic practice differences across regions.

The total eligible patient pool encompasses individuals across various stages of disease severity and organ involvement patterns. In the United States, diagnosed prevalent cases of microscopic polyangiitis by organ involvement show renal impairment as the most common manifestation, followed by lower respiratory tract involvement, cutaneous manifestation, gastrointestinal involvement, nervous system involvement, upper respiratory tract involvement, cardiovascular involvement, and eye involvement. For granulomatosis with polyangiitis cases in the UK, organ involvement patterns include upper respiratory tract, eye involvement, lower respiratory tract, cutaneous manifestation, renal impairment, and nervous system involvement.

Geographic segmentation across the 7MM reveals the United States as the largest market by patient population, accounting for the highest number of diagnosed prevalent cases in 2023, followed by Japan as the second-largest market. The EU4 countries (Germany, France, Italy, Spain) and the UK collectively represent a significant portion of the global patient population, with granulomatosis with polyangiitis accounting for the highest number of cases in these regions. The forecast period from 2024 to 2034 anticipates continued growth in diagnosed cases, driven by improved diagnostic capabilities, increased disease awareness, and enhanced healthcare access across all geographic regions within the 7MM framework.

Discover evolving trends in the ANCA-Associated Vasculitis patient pool forecasts @ ANCA-Associated Vasculitis Epidemiology Analysis.

Key ANCA-associated Vasculitis Companies and Treatment Market

The clinical and regulatory landscape for ANCA-associated Vasculitis treatment is characterized by a dynamic ecosystem of established therapies and emerging innovations that collectively address the complex pathophysiology of these rare autoimmune conditions. Current treatment options follow a well-established two-phase approach consisting of remission-induction therapy utilizing cyclophosphamide, rituximab, and high-dose steroids, followed by remission-maintenance treatment with methotrexate or azathioprine. The introduction of TAVNEOS (avacopan) as an FDA-approved adjunctive treatment represents a significant advancement in the therapeutic arsenal, offering patients a complement-targeted approach that addresses the underlying inflammatory cascade driving disease pathology.

ANCA-associated Vasculitis clinical pipeline activity demonstrates robust pharmaceutical industry engagement with multiple companies pursuing diverse therapeutic strategies across various development phases. Key players include GlaxoSmithKline (Depemokimab/GSK3511294), AstraZeneca (FASENRA/benralizumab), InflaRx, Staidson BioPharma, Bio-Thera Solutions, and ChemoCentryx/Amgen (TAVNEOS/avacopan). These companies represent a comprehensive approach to addressing different aspects of ANCA-associated Vasculitis pathophysiology, from complement inhibition to IL-5 pathway targeting, reflecting the scientific community’s sophisticated understanding of disease mechanisms.

Market positioning of current and emerging therapies reflects their distinct mechanisms of action and clinical applications within the treatment paradigm. TAVNEOS occupies a unique position as the first-in-class oral complement 5a receptor antagonist, offering patients an alternative to traditional immunosuppressive approaches while maintaining compatibility with standard therapy regimens. NUCALA (mepolizumab) and rituximab currently account for the highest market share among available therapies, establishing their central role in current treatment protocols.

Drug profiles reveal diverse approaches to targeting ANCA-associated Vasculitis pathophysiology. Depemokimab represents a next-generation humanized anti-IL-5 monoclonal antibody with extended half-life and improved affinity compared to approved therapies, currently advancing through Phase III development in the OCEAN trial. FASENRA employs a direct IL-5 receptor alpha binding mechanism that attracts natural killer cells to induce rapid eosinophil depletion, with the MANDARA trial demonstrating non-inferior remission rates compared to mepolizumab in a head-to-head comparison. Development milestones include positive Phase III results for FASENRA in September 2023 and the ongoing OCEAN trial for Depemokimab with anticipated data release after 2025. Commercial arrangements encompass various licensing deals and strategic collaborations, with Vifor Fresenius Medical Care Renal Pharma securing European marketing authorization for TAVNEOS and its inclusion in revised EULAR management recommendations, representing significant regulatory and clinical guideline achievements.

Discover which companies are innovating in the ANCA-Associated Vasculitis treatment landscape @ ANCA-Associated Vasculitis Competitive Landscape.

Conclusion

The ANCA-associated Vasculitis market stands at a pivotal juncture, with substantial growth potential driven by innovative therapeutic approaches and an expanding understanding of disease pathophysiology. DelveInsight’s comprehensive market analysis reveals a robust pipeline of targeted therapies poised to transform treatment outcomes for patients across the 7MM, while addressing the significant unmet medical needs that characterize this complex rare disease landscape. The convergence of novel mechanisms of action, improved diagnostic capabilities, and strategic pharmaceutical industry investment positions this market for sustained growth and enhanced patient outcomes throughout the forecast period, extending to 2034.

Table of Contents

1. Key Insights

2. Executive Summary of ANCA-Associated Vasculitis

3. Competitive Intelligence Analysis for ANCA-Associated Vasculitis

4. ANCA-Associated Vasculitis Market Overview at a Glance

5. ANCA-Associated Vasculitis: Disease Background and Overview

6. ANCA-Associated Vasculitis Patient Journey

7. ANCA-Associated Vasculitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. ANCA-Associated Vasculitis Unmet Needs

10. Key Endpoints of ANCA-Associated Vasculitis Treatment

11. ANCA-Associated Vasculitis Marketed Products

12. ANCA-Associated Vasculitis Emerging Therapies

13. ANCA-Associated Vasculitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of ANCA-Associated Vasculitis

17. KOL Views

18. ANCA-Associated Vasculitis Market Drivers

19. ANCA-Associated Vasculitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ANCA-Associated Vasculitis Market to Grow Significantly from USD 1.5 Billion in 2023, Fueled by Novel Biologics and Precision Medicine | DelveInsight

“Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology, and Market Forecast – 2034”

DelveInsight’s “Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology, and Market Forecast – 2034” report delivers a comprehensive analysis of the IC-MPGN market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways

• Market size projection: As per DelveInsight’s analysis, the total market size of IC-MPGN in the 7MM is expected to surge significantly by 2034, with the United States market alone growing significantly from approximately USD 12 million in 2023.

• Patient population data: The report provides the total IC-MPGN potential pool of more than 7K diagnosed prevalent cases across the 7MM in 2023, with the United States representing about 55% of these cases at approximately 3,770 diagnosed patients.

• Key companies: Leading IC-MPGN companies, such as Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others, are driving innovation in this ultra-rare kidney disease therapeutic area.

• Pipeline assets: Some of the key IC-MPGN pipeline therapies include Iptacopan (LNP023) from Novartis, Pegcetacoplan (APL-2) from Apellis Pharmaceuticals, and others targeting complement pathway inhibition.

• In August 2025, the FDA approved pegcetacoplan (EMPAVELI) by Apellis Pharmaceuticals as the first treatment specifically for patients 12 years and older with primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The approval was based on the Phase 3 VALIANT trial (NCT05067127), which demonstrated significant clinical benefits.

• Furthermore, Iptacopan (LNP023) is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 3 study specifically for idiopathic IC-MPGN.

Discover recent advancements in the IC-MPGN treatment landscape @ IC-MPGN Recent Developments.

IC-MPGN Market Dynamics

The IC-MPGN market represents an ultra-rare therapeutic area with significant unmet medical needs and substantial growth potential. Currently valued at approximately USD 12 million in the United States in 2023, the market is characterized by the lack of approved medications specifically indicated for IC-MPGN, creating a substantial demand for treatments that address the root cause of this progressive kidney disease.

IC-MPGN market drivers include increasing awareness of complement-mediated diseases, advances in understanding the pathophysiology of IC-MPGN, and the development of targeted complement inhibitors. The FDA approval of pegcetacoplan (EMPAVELI) by Apellis Pharmaceuticals, the first drug specifically approved for IC-MPGN heightens the optimisim in this landscape, further propelling the market.

The disease is characterized by immune complex deposition in the glomeruli, triggering inflammation and damage that can lead to kidney failure within 5-10 years of diagnosis. Current treatment strategies involve supportive measures with or without traditional immunosuppression, showing limited effectiveness in slowing disease progression.

IC-MPGN epidemiology includes moe than 7K diagnosed prevalent cases across the 7MM, with adults representing about 90% of all cases, typically resulting from chronic infections, autoimmune disorders, or underlying conditions such as hepatitis C, systemic lupus erythematosus (SLE), or monoclonal gammopathy.

Clinical development activity is intensifying, with key assets advancing through Phase III trials. The IC-MPGN emerging therapies centers on targeted complement inhibition, addressing the underlying pathophysiology of IC-MPGN.

The IC-MPGN competitive landscape features established pharmaceutical companies leveraging their expertise in nephrology and complement biology. Currently the market currently relies heavily on off-label prescription medications, creating opportunities for companies developing targeted therapies. However, challenges exist in developing effective complement inhibitors due to the complexity of the complement system and its adaptive capabilities.

Furthermore, the IC-MPGN market outlook remains positive, driven by the anticipated launch of targeted therapies, increasing diagnosis rates, and growing recognition of complement-mediated kidney diseases. The market is expected to experience significant growth through 2034, supported by the entry of novel therapeutics that address the underlying disease mechanisms rather than merely providing symptomatic relief.

Download the IC-MPGN Market report to understand which factors are driving the therapeutic market @ IC-MPGN Market Trends.

IC-MPGN Epidemiology

The IC-MPGN epidemiology across the 7MM reveals a rare but significant patient population requiring specialized therapeutic intervention. In 2023, more 7K diagnosed prevalent cases were identified across the seven major markets, representing a substantial patient population affected by this ultra-rare kidney disease. The United States dominates the global patient population, accounting for approximately 55% of all cases with around 3,770 diagnosed patients, followed by Japan as the second-largest market.

The IC-MPGN epidemiology geographic distribution shows notable variations across the 7MM regions. Within the EU4 countries and the United Kingdom, Germany represents the largest patient population, followed by Spain, while Italy demonstrates the lowest number of cases. This distribution pattern reflects both demographic factors and potentially differential diagnostic capabilities across these regions. Japan shows a distinct age distribution pattern, with adults being significantly more prevalent compared to the pediatric population, consistent with the global trend of adult predominance in IC-MPGN cases.

The IC-MPGN epidemiology age-specific segmentation reveals that approximately 90% of all IC-MPGN cases occur in adults, primarily due to underlying conditions that develop over time, including chronic infections, autoimmune disorders, hepatitis C, systemic lupus erythematosus, and monoclonal gammopathy. These conditions lead to persistent immune complex formation, triggering complement system activation and resulting in progressive kidney damage. The pediatric population represents a smaller but clinically significant segment requiring specialized care approaches.

Additionally, DelveInsight’s gender-specific analysis indicates a relatively balanced distribution between male and female patients, though specific regional variations exist across the 7MM. The total treated cases represent a subset of the diagnosed prevalent population, reflecting current treatment limitations and the challenge of managing this progressive disease with existing therapeutic options. The forecast period from 2024 to 2034 anticipates gradual growth in diagnosed cases, driven by improved awareness, enhanced diagnostic capabilities, and better recognition of IC-MPGN as a distinct clinical entity separate from other forms of membranoproliferative glomerulonephritis.

Discover evolving trends in the IC-MPGN patient pool forecasts @ IC-MPGN Epidemiology Analysis.

Key IC-MPGN Companies and Treatment Market

The clinical and regulatory IC-MPGN landscape is evolving rapidly, with current treatment options limited to supportive care and off-label immunosuppressive therapies. Traditional approaches include renin-angiotensin-aldosterone system inhibitors, immunosuppressants such as corticosteroids, calcineurin inhibitors, and mycophenolate mofetil-based treatments, though these show limited effectiveness in slowing disease progression. The limited IC-MPGN approved therapies has created a significant treatment gap that emerging complement inhibitors aim to address.

The IC-MPGN clinical pipeline activity is concentrated around complement pathway modulation, with two leading companies advancing promising therapeutics through late-stage development. Key players include Novartis Pharmaceuticals (stock symbol: NVS) with iptacopan (LNP023) and Apellis Pharmaceuticals (stock symbol: APLS) with pegcetacoplan (APL-2), both targeting different aspects of the complement cascade to address the underlying pathophysiology of IC-MPGN.

Market positioning of these pipeline assets represents a paradigm shift from symptomatic management to targeted disease modification. Iptacopan functions as an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, discovered at the Novartis Institutes for BioMedical Research. Currently in Phase III clinical development, the drug has the potential to become the first targeted therapy to delay progression to dialysis in complement-related kidney diseases. Pegcetacoplan operates as a targeted C3 inhibitor designed to regulate excessive complement activation, utilizing a unique 15-amino acid cyclic peptide conjugated to polyethylene glycol that binds to C3 and C3b, directly preventing activation of C3, C5, and the alternative pathway.

Commercial arrangements include strategic collaborations, with Apellis partnering with Sobi for the VALIANT study results announcement. Both companies have established comprehensive development programs spanning multiple complement-related diseases, positioning their assets for potential label expansions beyond IC-MPGN. The regulatory pathway for these novel therapies benefits from the rare disease designation and the significant unmet medical need, potentially facilitating accelerated development timelines and priority review processes.

Discover which companies are innovating in the IC-MPGN treatment landscape @ IC-MPGN Competitive Landscape.

Conclusion

DelveInsight’s comprehensive analysis of the IC-MPGN market reveals a therapeutic area poised for transformation through targeted complement inhibition. With approximately 7,100 patients across the 7MM currently lacking effective treatment options, the anticipated market growth driven by iptacopan and pegcetacoplan represents a significant advancement for this ultra-rare kidney disease. The convergence of improved understanding of complement-mediated pathophysiology, positive late-stage clinical results, and the substantial unmet medical need positions the IC-MPGN market for meaningful expansion through 2034. As these innovative therapies progress toward regulatory approval and commercial launch, they offer the potential to fundamentally change the treatment paradigm and improve outcomes for patients suffering from this progressive and debilitating condition.

Table of Contents

1. Key Insights

2. Executive Summary of IC-MPGN

3. Competitive Intelligence Analysis for IC-MPGN

4. IC-MPGN Market Overview at a Glance

5. IC-MPGN: Disease Background and Overview

6. IC-MPGN Patient Journey

7. IC-MPGN Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. IC-MPGN Unmet Needs

10. Key Endpoints of IC-MPGN Treatment

11. IC-MPGN Marketed Products

12. IC-MPGN Emerging Therapies

13. IC-MPGN: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of IC-MPGN

17. KOL Views

18. IC-MPGN Market Drivers

19. IC-MPGN Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IC-MPGN Therapeutics Market Expected to Grow With Complement Inhibitor Therapies: First FDA Approvals, Clinical Pipeline | DelveInsight

“Essential Thrombocythemia Market Insight, Epidemiology And Market Forecast – 2034”

DelveInsight’s “Essential Thrombocythemia Market Insight, Epidemiology And Market Forecast – 2034” report delivers a comprehensive analysis of the Essential Thrombocythemia market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways

• Market size projection: As per DelveInsight’s analysis, the total Essential Thrombocythemia market size in the 7MM is expected to surge significantly by 2034, with the current market valued at approximately $417 million in 2024.

• Patient population data: The report provides the total Essential Thrombocythemia potential pool of approximately 168K diagnosed cases in the United States alone in 2024, with around 85K first-line treated patients.

• Key companies: Leading Essential Thrombocythemia companies, such as pharma&, AOP Orphan Pharmaceuticals AG, Merck Sharp and Dohme, Novartis, Incyte Corporation, PharmaEssentia, and others are actively developing innovative therapeutic solutions.

• Essential Thrombocythemia currently has very limited commercially available treatments, with anagrelide (Agrylin) being the only FDA-approved drug specifically for Essential Thrombocythemia.

• Pipeline assets: Some of the key Essential Thrombocythemia pipeline therapies include BESREMI (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib (CPI-0610), Dencatistat (STP 938), INCA033989, and VAC85135.

• Recent developments: In August 2024, pharma& GmbH announced that the European Commission had granted marketing authorization for a Type II variation for PEGASYS (peginterferon alfa-2a) as a monotherapy treatment for adults with Essential Thrombocythemia, representing the only drug approved specifically for ET treatment, exclusively authorized in Europe.

• In June 2025, at the 30th Congress of the European Hematology Association (EHA2025) in Milan, researchers presented the largest study to date on rare MPL-mutant Essential Thrombocythemia. This landmark multinational study, led by Prof. Steffen Koschmieder from RWTH Aachen University, profiled outcomes in over 300 patients across 37 institutions.

• Geographic distribution: The United States accounts for approximately 60% of the total market share, representing around $250 million in 2024, followed by Japan as the second-largest market.

• Treatment landscape transformation: Among emerging therapies, BESREMI and Bomedemstat appear to be the drugs that can potentially transform the ET market, with BESREMI expected to generate the highest revenue by 2034.

Discover recent advancements in the Essential Thrombocythemia treatment landscape @ Essential Thrombocythemia Recent Developments.

Essential Thrombocythemia Market Dynamics

The Essential Thrombocythemia market represents a specialized segment within hematologic malignancies, characterized by significant unmet medical needs and emerging therapeutic opportunities. With a current market size of approximately $417 million across the 7MM in 2024, the market demonstrates substantial growth potential driven by increasing disease awareness, improved diagnostic capabilities, and innovative pipeline developments.

Market momentum is currently propelled by several key factors, including the recognition of Essential Thrombocythemia as a chronic myeloproliferative neoplasm requiring specialized management approaches. The disease primarily affects women over 50 years of age and is characterized by elevated platelet counts exceeding normal ranges, often discovered incidentally during routine blood work. The market evolution reflects a growing understanding of the genetic underpinnings of the disease, particularly the role of JAK2, CALR, and MPL gene mutations, which serve as driver mutations in approximately 90% of adult cases.

The current and emerging Essential Thrombocythemia therapies centers on addressing the fundamental pathophysiology of Essential Thrombocythemia, which involves overproduction of hematopoietic cells and increased thrombotic risk. Current treatment approaches focus on cytoreductive therapy to manage platelet counts and prevent thromboembolic complications, utilizing agents such as hydroxyurea, anagrelide, and interferon-alpha in combination with aspirin therapy. The Essential Thrombocythemia therapeutic landscape is evolving toward more targeted approaches that address the underlying molecular mechanisms driving the disease.

The Essential Thrombocythemia clinical development space is gaining momentum with several promising candidates advancing through various phases of development. The pipeline includes both novel mechanisms of action and improved formulations of existing therapeutic classes. Phase III trials are evaluating BESREMI (ropeginterferon alfa-2b) and Bomedemstat (MK-3543/IMG-7289), while Phase I/II studies are exploring Pelabresib (CPI-0610) and other innovative approaches targeting specific pathways involved in myeloproliferative disorders.

The Essential Thrombocythemia competitive landscape is characterized by both established pharmaceutical companies and specialized biotechnology firms focusing on hematologic malignancies. The market presents significant opportunities for companies developing targeted therapies that can address the limited treatment options currently available, particularly given that only one therapy has received specific approval for Essential Thrombocythemia treatment in Europe, with no FDA-approved therapies in the United States.

Future market outlook appears promising, with expectations for substantial growth driven by the anticipated approval and launch of pipeline assets, increased disease awareness among healthcare providers, and expanding treatment paradigms that emphasize personalized medicine approaches based on genetic profiling and risk stratification.

Download the Essential Thrombocythemia Market report to understand which factors are driving the therapeutic market @ Essential Thrombocythemia Market Trends.

Essential Thrombocythemia Epidemiology

The Essential Thrombocythemia epidemiological landscape across the 7MM reveals significant disease burden with distinct demographic and geographic patterns. The total diagnosed prevalent cases across the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan demonstrate the global impact of this chronic myeloproliferative neoplasm, with the United States representing the largest patient population at approximately 167,450 diagnosed cases in 2024.

The Essential Thrombocythemia epidemiological segmentation reveals important demographic characteristics that influence treatment approaches and market dynamics. Gender-specific analysis indicates a predominant female distribution, with women accounting for 64% of cases compared to 36% for males in 2024. Furthermore, age-specific segmentation demonstrates that patients over 60 years of age represent the highest burden, accounting for approximately 110K cases in the United States, followed by the 40-60 years age group and patients under 40 years of age.

The genetic mutation profile provides crucial insights into disease heterogeneity, with JAK2 mutations responsible for the majority of Essential Thrombocythemia cases, accounting for 75% of diagnosed patients. CALR and MPL mutations constitute the remaining proportion, while approximately 20% of patients may present as triple-negative for all three driver mutations. This molecular segmentation has significant implications for treatment selection and prognosis, as different mutation profiles may respond differently to targeted therapies.

Geographic distribution within the 7MM shows Germany leading among EU4 and UK countries, accounting for more than 20% of diagnosed cases in 2024, followed by France and the United Kingdom. Japan represents a significant market within the Asia-Pacific region, contributing substantially to the overall patient pool. Risk stratification reveals that symptom-specific cases vary considerably, with many patients remaining asymptomatic at diagnosis, discovered incidentally through routine blood testing, revealing elevated platelet counts.

The total Essential Thrombocythemia eligible patient pool encompasses approximately 85,000 first-line treated patients in the United States in 2024, representing roughly 51% of the diagnosed population receiving active therapeutic intervention. The treatment gap reflects the asymptomatic nature of many cases and the risk-stratified approach to therapy initiation. The forecast period extending through 2034 anticipates steady growth in diagnosed cases due to improved awareness, enhanced diagnostic capabilities, and aging demographics, with corresponding increases in the treated patient population as therapeutic options expand and treatment guidelines evolve.

Discover evolving trends in the Essential Thrombocythemia patient pool forecasts @ Essential Thrombocythemia Epidemiology Analysis.

Key Essential Thrombocythemia Companies and Treatment Market

The Essential Thrombocythemia treatment landscape is characterized by a combination of established therapies and emerging innovative approaches, with several key pharmaceutical companies leading development efforts across different phases of clinical investigation. The current clinical and regulatory environment reflects significant unmet medical needs, particularly in the United States, where no therapies have received FDA approval specifically for Essential Thrombocythemia treatment, contrasting with Europe, where PEGASYS has achieved regulatory authorization.

Current treatment options focus primarily on cytoreductive approaches aimed at managing platelet counts and reducing thrombotic risk. The therapeutic arsenal includes hydroxyurea, anagrelide, and interferon-alpha preparations, typically used in combination with aspirin therapy based on individual risk stratification. Busulfan, clopidogrel, and anticoagulants serve as additional therapeutic options depending on patient-specific factors and treatment responses. The treatment paradigm emphasizes risk-based management, with therapy decisions guided by patient age, prior thrombotic events, and platelet count levels.

The Essential Thrombocythemia clinical pipeline activity demonstrates robust development efforts with multiple mechanisms of action under investigation. Key Essential Thrombocythemia companies include PharmaEssentia and AOP Orphan Pharmaceuticals AG (BESREMI – ropeginterferon alfa-2b), which represents a long-acting pegylated interferon with enhanced pharmacological properties currently in Phase III development. The company anticipates regulatory submission to the FDA by the end of 2025 following successful polycythemia vera approval. Merck Sharp and Dohme (Bomedemstat – MK-3543/IMG-7289) is advancing a small molecule LSD1 inhibitor through Phase III trials, with multiple regulatory designations including Orphan Drug Designation and Fast Track status for Essential Thrombocythemia and myelofibrosis indications.

Novartis contributes to the pipeline with Pelabresib (CPI-0610) in Phase I/II development, expanding the therapeutic approach to include BET protein inhibition as a novel mechanism for myeloproliferative neoplasm management. Additional pipeline assets include Dencatistat from Step Pharma, INCA033989, and VAC85135, representing diverse approaches to addressing the underlying pathophysiology of Essential Thrombocythemia.

The Essential Thrombocythemia therapeutic development milestones reflect accelerated regulatory pathways and specialized designations recognizing the significant unmet medical need in this patient population. The accumulation of Orphan Drug Designations, Fast Track Designations, and Priority Medicines scheme recognitions from regulatory authorities underscores the commitment to advancing therapeutic options for Essential Thrombocythemia patients. Recent clinical trial data presentations at major hematology conferences demonstrate the scientific rigor and clinical potential of these emerging therapies.

Commercial arrangements and strategic collaborations, such as the partnership between PharmaEssentia and AOP Orphan Pharmaceuticals for European market development, illustrate the global approach to Essential Thrombocythemia therapy commercialization. These arrangements leverage regional expertise and regulatory capabilities to maximize patient access to innovative therapies across different geographic markets.

Discover which companies are innovating in the Essential Thrombocythemia treatment landscape @ Essential Thrombocythemia Competitive Landscape.

Conclusion

The Essential Thrombocythemia market stands at a pivotal juncture with substantial growth opportunities driven by significant unmet medical needs and promising pipeline developments. DelveInsight’s comprehensive analysis reveals a market valued at $417 million in 2024 across the 7MM, with the United States representing the dominant market segment. The current landscape is characterized by limited approved therapeutic options, particularly in the United States, creating substantial opportunities for emerging therapies to transform patient care. With key pipeline assets including BESREMI and Bomedemstat positioned to potentially reshape the treatment paradigm, and approximately 167,450 diagnosed cases in the United States alone representing a substantial patient population in need of effective therapies, the market outlook through 2034 appears highly favorable. The convergence of improved understanding of disease pathophysiology, targeted therapeutic approaches, and accelerated regulatory pathways positions the Essential Thrombocythemia market for significant expansion, ultimately benefiting patients who have historically had limited treatment options for this chronic myeloproliferative neoplasm.

Table of Contents

1. Key Insights

2. Executive Summary of Essential Thrombocythemia

3. Competitive Intelligence Analysis for Essential Thrombocythemia

4. Essential Thrombocythemia Market Overview at a Glance

5. Essential Thrombocythemia: Disease Background and Overview

6. Essential Thrombocythemia Patient Journey

7. Essential Thrombocythemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Essential Thrombocythemia Unmet Needs

10. Key Endpoints of Essential Thrombocythemia Treatment

11. Essential Thrombocythemia Marketed Products

12. Essential Thrombocythemia Emerging Therapies

13. Essential Thrombocythemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Essential Thrombocythemia

17. KOL Views

18. Essential Thrombocythemia Market Drivers

19. Essential Thrombocythemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Essential Thrombocythemia Market to Grow Significantly from $417 Million in 2024, Driven by Shifts Toward Targeted Therapies and Precision Medicine | DelveInsight

“Atypical Hemolytic Uremic Syndrome (aHUS) Market Insight, Epidemiology And Market Forecast – 2034”

DelveInsight’s “Atypical Hemolytic Uremic Syndrome (aHUS) Market Insight, Epidemiology And Market Forecast – 2034” report delivers a comprehensive analysis of the atypical hemolytic uremic syndrome market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways

• Market size projection: As per DelveInsight’s analysis, the total atypical hemolytic uremic syndrome market size in the 7MM is expected to surge significantly by 2034, with the market valued at approximately USD 1.3 billion in 2023 and projected to grow at a CAGR of approximately 4% during the forecast period (2024-2034).

• Patient population data: The report provides the total atypical hemolytic uremic syndrome potential pool of nearly 5K diagnosed cases across the 7MM in 2023, with the United States accounting for approximately 3.5K cases, representing the highest burden globally.

• Key companies: Leading atypical hemolytic uremic syndrome companies, such as Alexion Pharmaceuticals (acquired by AstraZeneca), Novartis Pharmaceuticals, Hoffmann-La Roche/Chugai Pharmaceutical, and NovelMed Therapeutics, are driving innovation in this therapeutic landscape.

• Pipeline assets: Some of the key atypical hemolytic uremic syndrome therapies in the pipeline include iptacopan (LNP023/FABHALTA) by Novartis, crovalimab (RG6107/SKY59) by Hoffmann-La Roche/Chugai, and NM8074 by NovelMed Therapeutics, alongside the currently marketed therapies eculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS) by Alexion Pharmaceuticals.

• In May 2024, the FDA granted approval to Bkemv (eculizumab-aeeb), marking the first interchangeable biosimilar to SOLIRIS (eculizumab) for treating both paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome.

• A major real world effectiveness study of eculizumab in atypical hemolytic uremic syndrome was published in June 2025 representing the largest single-center cohort (n=17) of eculizumab-treated aHUS patients. The study emphasized the critical importance of treatment initiation timing, categorizing patients as Early Initiators (treatment within 7 days) versus Delayed Initiators (treatment beyond 7 days).

• According to a recent study published in August 2025 shows that most people with atypical hemolytic uremic syndrome who are stable on SOLIRIS (eculizumab) can stop treatment after at least six months without having a relapse, provided that they’re carefully monitored.

Discover recent advancements in the Atypical Hemolytic Uremic Syndrome treatment landscape @ Atypical Hemolytic Uremic Syndrome Recent Developments.

Atypical Hemolytic Uremic Syndrome Market Dynamics

The atypical hemolytic uremic syndrome market represents a critical segment within rare disease therapeutics, characterized by significant unmet medical needs and premium pricing strategies. The current market size of approximately USD 1,300 million in 2023 across the 7MM reflects the high-value, low-volume nature of this therapeutic area, with the United States commanding the largest market share at approximately 70%.

Market momentum is being driven by several key factors, including increased disease awareness, improved diagnostic capabilities, and the introduction of innovative complement inhibition therapies. The transition from traditional supportive care approaches to targeted complement inhibition has fundamentally transformed the treatment paradigm, offering patients significantly improved prognosis and quality of life outcomes. However, the market faces challenges including premium pricing that limits accessibility, safety concerns with current treatments, lack of definitive diagnostic criteria, and the looming threat of generic competition.

The current and emerging atypical hemolytic uremic syndrome therapies centers on complement system inhibition, particularly targeting the C5 complement protein and alternative pathway components. Atypical hemolytic uremic syndrome is fundamentally a complement-mediated disorder, where abnormal activation leads to thrombotic microangiopathy affecting primarily the kidneys. The complement cascade represents a validated therapeutic target, with both current therapies eculizumab and ravulizumab functioning as C5 inhibitors, while emerging therapies like iptacopan target factor B in the alternative pathway.

The atypical hemolytic uremic syndrome clinical development activity remains robust despite the limited patient population, with multiple Phase III and Phase II programs advancing. Novartis’s iptacopan represents a potentially transformative oral therapy expected to generate over USD 500 million by 2034, while Roche’s crovalimab offers potential advantages through its recycling antibody technology. The competitive landscape is evolving beyond Alexion’s current dominance, with multiple pharmaceutical companies recognizing the commercial potential despite the rare disease designation.

The primary challenges facing market development include the extremely high cost of current therapies, which creates access barriers and limits commercial uptake, alongside diagnostic complexities that can delay appropriate treatment initiation. However, significant opportunities exist, particularly around oral formulations that could improve patient compliance and reduce healthcare system burden. The market outlook remains positive, with growth drivers including expanding geographic access, improved diagnostic approaches, and the potential for combination therapies addressing different aspects of complement activation.

Download the Atypical Hemolytic Uremic Syndrome Market report to understand which factors are driving the therapeutic market @ Atypical Hemolytic Uremic Syndrome Market Trends.

Atypical Hemolytic Uremic Syndrome Epidemiology

The atypical hemolytic uremic syndrome epidemiological landscape across the seven major markets reveals a rare but clinically significant patient population requiring specialized therapeutic intervention. According to DelveInsight’s epidemiological forecasting model, the total atypical hemolytic uremic syndrome diagnosed cases in the 7MM reached approximately 5K in 2023, with projections indicating continued growth throughout the forecast period extending to 2034.

The atypical hemolytic uremic syndrome epidemiological segmentation demonstrates distinct patterns across age groups and geographic regions, with adolescent and adult populations representing approximately 80% of diagnosed cases, translating to roughly 4K cases, while pediatric patients account for the remaining 700 cases in 2023. This age distribution reflects the disease’s tendency to manifest more commonly in older populations, though pediatric cases represent a particularly vulnerable segment requiring specialized treatment approaches.

Geographic segmentation across the 7MM reveals significant variations in disease burden and healthcare infrastructure capabilities. The United States dominates the patient population with approximately 3.5K diagnosed cases in 2023, representing the largest single market for therapeutic interventions. Among the European Union countries and the United Kingdom, Germany accounts for the highest number of prevalent cases, while Spain represents the smallest patient population within this regional grouping.

The total eligible patient pool encompasses both diagnosed and potentially undiagnosed cases, with diagnostic challenges contributing to potential underreporting of the true disease prevalence. The report indicates that diagnostic complexity, particularly in the absence of family history, creates barriers to timely identification and treatment initiation. Total treated cases represent a subset of the diagnosed population, influenced by factors including therapeutic access, reimbursement policies, and clinical decision-making regarding treatment timing and selection.

Forecast period projections through 2034 anticipate steady growth in diagnosed cases across all major markets, driven by improved diagnostic awareness, enhanced healthcare infrastructure, and expanded access to specialized nephrology care. The epidemiological trends suggest that while atypical hemolytic uremic syndrome remains a rare disease, the absolute number of patients requiring therapeutic intervention will continue to expand, supporting the commercial viability of both current and emerging treatment options.

Discover evolving trends in the Atypical Hemolytic Uremic Syndrome patient pool forecasts @ Atypical Hemolytic Uremic Syndrome Epidemiology Analysis.

Key Atypical Hemolytic Uremic Syndrome Companies and Treatment Market

The clinical and regulatory landscape for atypical hemolytic uremic syndrome is characterized by a limited but highly effective array of current treatment options, centered primarily around complement inhibition therapy. The market is currently dominated by two approved therapies, both developed by Alexion Pharmaceuticals prior to its acquisition by AstraZeneca in July 2021: eculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS), which function as complement C5 inhibitors and have established the therapeutic standard of care.

The atypical hemolytic uremic syndrome clinical pipeline activity demonstrates significant pharmaceutical industry interest despite the rare disease designation, with multiple companies advancing innovative therapeutic approaches through various development phases. Key atypical hemolytic uremic syndrome companies include Novartis Pharmaceuticals (iptacopan/LNP023), Hoffmann-La Roche/Chugai Pharmaceutical (crovalimab/RG6107), and NovelMed Therapeutics (NM8074), each representing distinct mechanistic approaches to complement inhibition.

Market positioning of emerging therapies reflects differentiated value propositions designed to address current treatment limitations. Iptacopan, positioned as a first-in-class oral factor B inhibitor, represents a potentially paradigm-shifting approach offering convenient twice-daily oral administration compared to current intravenous therapies. This oral formulation could significantly improve patient quality of life and reduce healthcare system burden associated with repeated infusions.

The atypical hemolytic uremic syndrome drug profiles reveal sophisticated approaches to complement system modulation, with crovalimab utilizing recycling antibody technology to potentially extend dosing intervals, while iptacopan targets the alternative pathway at the factor B level rather than the terminal complement components. These mechanistic differences may translate into distinct clinical profiles, safety considerations, and patient selection criteria as the competitive landscape evolves.

Development milestones indicate accelerating clinical progress, with iptacopan in Phase III development expected to complete by December 2024, and crovalimab advancing through two Phase III trials with completion dates ranging from March 2024 to December 2025. These timelines suggest potential market entry within the forecast period, creating competitive dynamics that could influence pricing strategies and market share distribution.

Commercial arrangements and strategic collaborations reflect the high-value nature of this therapeutic area, with Alexion’s acquisition by AstraZeneca representing one of the largest rare disease transactions in pharmaceutical history. The premium pricing of current therapies, while creating access challenges, also demonstrates the substantial commercial potential for innovative treatments that can demonstrate meaningful clinical advantages.

Discover which companies are innovating in the Atypical Hemolytic Uremic Syndrome treatment landscape @ Atypical Hemolytic Uremic Syndrome Competitive Landscape.

Conclusion

The atypical hemolytic uremic syndrome market represents a compelling intersection of significant unmet medical need and substantial commercial opportunity within the rare disease landscape. DelveInsight’s comprehensive analysis reveals a market poised for transformation, with current annual revenues of approximately USD 1,300 million in 2023 projected to grow at a 4% CAGR through 2034, driven by innovative therapeutic approaches and expanding patient access.

The emergence of oral complement inhibition through iptacopan and next-generation monoclonal antibodies like crovalimab promises to address current treatment limitations while potentially expanding the treatable patient population. With robust clinical development activity and strong pharmaceutical industry commitment, the aHUS market is positioned to deliver improved patient outcomes while maintaining attractive commercial returns for innovative companies addressing this rare but serious hematological condition.

Table of Contents

1. Key Insights

2. Executive Summary of Atypical Hemolytic Uremic Syndrome

3. Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome

4. Atypical Hemolytic Uremic Syndrome Market Overview at a Glance

5. Atypical Hemolytic Uremic Syndrome: Disease Background and Overview

6. Atypical Hemolytic Uremic Syndrome Patient Journey

7. Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Atypical Hemolytic Uremic Syndrome Unmet Needs

10. Key Endpoints of Atypical Hemolytic Uremic Syndrome Treatment

11. Atypical Hemolytic Uremic Syndrome Marketed Products

12. Atypical Hemolytic Uremic Syndrome Emerging Therapies

13. Atypical Hemolytic Uremic Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome

17. KOL Views

18. Atypical Hemolytic Uremic Syndrome Market Drivers

19. Atypical Hemolytic Uremic Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atypical Hemolytic Uremic Syndrome Market Poised for Expansion with 4% CAGR Through 2034, Driven by Oral Therapies, Biosimilars, and Expanding Patient Pool | DelveInsight

“Astigmatism – Market Insight, Epidemiology And Market Forecast – 2032”

Develnsight’s latest report, “Astigmatism – Market Insight, Epidemiology And Market Forecast – 2032”, combines robust epidemiological data with market trends, competitive landscape analysis, and assessments of the patient journey, providing valuable insights into the rapidly expanding astigmatism market.

Astigmatism is a common refractive error affecting a large global population, creating a substantial demand for corrective measures and vision enhancement technologies. The astigmatism market is projected to experience steady growth in the 7MM with a robust CAGR, driven by technological advancements in vision correction methods, rising awareness about eye health, and various demographic factors such as age and genetic predisposition. While the exact genetic mechanisms are not fully understood, several studies have indicated hereditary patterns whereby astigmatism often runs in families.

Download the Astigmatism market report to understand which factors are driving the Astigmatism treatment market @ Astigmatism Market Trends.

The astigmatism epidemiology in the DelveInsight report reveals a significant burden. Astigmatism prevalence in the general population varied from 8 to 62%, with higher rates in individuals aged 70 years or older. Furthermore, the prevalence of with-the-rule astigmatism is more significant in individuals aged 40 years or younger, while rates of against-the-rule and oblique astigmatism tend to increase with age.

Gain valuable insights into the Astigmatism patient pool across the 7MM @ Astigmatism Epidemiology Analysis.

The report also discusses current and emerging trends in astigmatism treatment. The current treatment landscape is diverse, offering both non-invasive and surgical options tailored to the severity of the condition and patient preferences.

Non-invasive treatments remain the most common approach to managing astigmatism. Prescription eyeglasses and contact lenses, particularly toric lenses, are widely utilized to correct the uneven curvature of the cornea, providing a simple and cost-effective solution for patients.

Refractive surgeries such as LASIK and PRK are highly effective options. Another surgical alternative involves implanting intraocular lenses during cataract surgery or refractive lens exchange. These lenses offer long-term vision correction and especially benefit older patients undergoing cataract surgery.

Orthokeratology presents a non-surgical alternative for correcting astigmatism, particularly in pediatric patients or those not yet ready for surgery, using specially designed rigid contact lenses overnight to temporarily reshape the cornea.

In January 2025, the MEL 90 excimer laser by Carl Zeiss Meditec AG received the FDA approval for treating myopia, hyperopia, and mixed astigmatism, marking a significant milestone in refractive surgery. Equipped with the Triple-A ablation algorithm, the MEL 90 offers highly predictable, tissue-conserving procedures and can ablate 1 diopter in just 1.3 seconds during LASIK for myopia.

Emerging therapies are transforming the astigmatism treatment landscape by offering safer, minimally invasive, and highly effective alternatives to traditional surgical procedures. These innovations promise quicker recovery times and enhanced precision, addressing unmet needs in astigmatism management.

Notable developments include the introduction of toric intraocular lenses (IOLs) specifically designed to correct astigmatism during cataract surgery or refractive lens exchange. Another emerging alternative is SMILE (Small Incision Lenticule Extraction), a flapless procedure utilizing femtosecond laser technology, which is particularly suitable for patients with dry eyes or thin corneas.

Stay ahead with the latest breakthroughs, FDA approvals, and eco-friendly innovations shaping the future of the Astigmatism treatment landscape. Visit Astigmatism Recent Developments.

As these emerging treatments gain traction, they address key unmet needs in astigmatism management, such as minimizing visual disturbances and expanding eligibility for procedures. With ongoing research and development in areas like gene-editing technologies, such as CRISPR/Cas9, and regenerative medicine, such as stem cell therapy to regenerate damaged ocular tissues, the future of the astigmatism treatment market looks increasingly promising.

Table of contents

Related Reports

Dry Age-Related Macular Degeneration Pipeline Insight

Dry Age-Related Macular Degeneration Pipeline Insight provides comprehensive insights about the Dry Age-Related Macular Degeneration pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Dry Age-Related Macular Degeneration manufacturers, including Belite Bio (NASDAQ: BLTE), Inflammx Therapeutics, Ocugen (NASDAQ: OCGN), OliX Pharmaceuticals, Gensight Biologics (NASDAQ: GNST), Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics (NASDAQ: CGTX), Aviceda Therapeutics, Galimedix Therapeutics, Mitotech (NASDAQ: MITO), Annexon, Inc. (NASDAQ: ANNX), NGM Biopharmaceuticals (NASDAQ: NGM), Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, and ONL Therapeutics, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Astigmatism Market Expansion Driven by Refractive Surgeries, Emerging Non-Surgical Alternatives, and Genetic Insights | DelveInsight